Antineoplastic effects of liposomal short interfering RNA treatment targeting BLIMP1/PRDM1 in primary effusion lymphoma

Haematologica

Volumn 100, Issue 11, 2015, Pages e467-e470

  Riva, Giovanni ^a   Lagreca, Ivana ^a   Mattiolo, Adriana ^b   Belletti, Daniela ^c   Lignitto, Laura ^b   Barozzi, Patrizia ^a   Ruozi, Barbara ^c   Vallerini, Daniela ^a   Quadrelli, Chiara ^a   Corradini, Giorgia ^a   Forghieri, Fabio ^a   Marasca, Roberto ^a   Narni, Franco ^a   Tosi, Giovanni ^c   Forni, Flavio ^c   Vandelli, Maria Angela ^c   Amadori, Alberto ^b,d   Chieco Bianchi, Luigi ^d   Potenza, Leonardo ^a   Calabrò, Maria Luisa ^b   Luppi, Mario ^a   more..

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

Author keywords

BLIMP1 PRDM1; Liposomes; PEL; RNAi; siRNA

Indexed keywords

B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; CIDOFOVIR; LIPOPLEX; LIPOSOME; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; PRDM1 PROTEIN, HUMAN; REPRESSOR PROTEIN; TUMOR PROTEIN;

ARTICLE; CELL CYCLE; CLINICAL TRIAL (TOPIC); DOWN REGULATION; DRUG TARGETING; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE SILENCING; HUMAN; NONHUMAN; PRIMARY EFFUSION LYMPHOMA; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; FEMALE; GENETICS; LYMPHOMA, PRIMARY EFFUSION; MALE; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; FEMALE; HUMANS; LIPOSOMES; LYMPHOMA, PRIMARY EFFUSION; MALE; NEOPLASM PROTEINS; REPRESSOR PROTEINS; RNA, SMALL INTERFERING;

EID: 84946198445     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2015.126854     Document Type: Article

References (15)

1. Bumcrot D, Manoharan M, Koteliansky V, Sah DWY. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol. 2006;2(12):711–719
2. Davis ME, Zuckerman JE, Choi CH, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010;464(7291):1067-1070
3. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 2009;8(2):129-138
4. Ozpolat B, Sood AK, Lopez-Berestein G. Liposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliv Rev. 2014;66:110-116
5. Coelho T, Adams D, Silva A, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013;369(9):819-829
6. Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet. 2014;383(9911):60-68
7. Jenner RG, Maillard K, Cattini N, et al. Kaposi's sarcoma-associated herpesvirus-infected primary effusion lymphoma has a plasma cell gene expression profile. Proc Natl Acad Sci USA. 2003;100(18):10399-10404
8. Carbone A, Gloghini A. KSHV/HHV8-associated lymphomas. Br J Haematol. 2008;140(1):13-24
9. Godfrey A, Anderson J, Papanastasiou A, Takeuchi Y, Boshoff C. Inhibiting primary effusion lymphoma by lentiviral vectors encoding short hairpin RNA. Blood. 2005;105(6):2510-2518
10. Ruozi B, Riva G, Belletti D, et al. Immunoliposomal systems targeting primary effusion lymphoma: in vitro study. Nanomedicine (Lond). 2010;5(7):1051-1064
11. Ruozi B, Riva G, Belletti D, et al. Cidofovir-loaded liposomes: an intro-study using BCBL-1 cell line as a model for primary effusion lymphoma. Eur J Pharm Sci. 2010;41(2):254-264
12. Belletti D, Riva G, Tosi G, et al. Novel polymeric/lipidic hybrid systems (PLHs) for effective cidofovir delivery: preparation, characterization and comparative in vitro study with polymeric particles and liposomes. Int J Pharm. 2011;413(1-2):220-228
13. Luppi M, Trovato R, Barozzi P, et al. Treatment of herpesvirus associated primary effusion lymphoma with intracavity cidofovir. Leukemia. 2005;19(3):473-476
14. Calabrò ML, Gasperini P, Di Gangi IM, et al. Antineoplastic activity of lentiviral vectors expressing interferon-alpha in a preclinical model of primary effusion lymphoma. Blood. 2009;113(19):4525-4533
15. Lin FR, Kuo HK, Ying HY, Yang FH, Lin KI. Induction of apoptosis in plasma cells by B lymphocyte-induced maturation protein-1 knockdown. Cancer Res. 2007;67(24):11914-11923.